

Industry Expert Theater

Clinical Considerations in Stroke or Transient Ischemic Attack

Date: Sunday, December 20, 2020

Time: 5:30 - 6 pm EST

Presenter: Dr. Richard J. Kraft, PharmD
Medical Science Liaison, Medical Affairs
CVMD
AstraZeneca



Rick is has been a medical science liaison with AstraZeneca for since 2018. He graduated from UB School of Pharmacy and Pharmaceutical Sciences in 2005 with his PharmD degree. He completed his PGY1 residency with UB/BMG in 2008 with a focus on ambulatory care. He has practiced in a variety of health care settings and in different roles throughout his career from regional insurance payer, retail pharmacy, adjunct faculty, hospital, ambulatory care and transition of care.

Prior to joining AstraZeneca he had most recently led the initiative to build a pharmacy team to assume to responsibility of medication history for all admitted patients to Buffalo General Medical center and from 2008 until 2017 as director of pharmacy services for Catholic Medical Partners developed and led various pharmacy services initiatives across care settings and as part of one of the first shared savings ACOs in the nation.

Rick continues to strive to understand the healthcare system as a whole always searching for opportunities to improve it. In particular, he works to uncover ways to utilize the skills of pharmacists and opportunities to further develop those skills to enhance the system and patient care. As a medical science liaison he supports clinicians in identifying and working to fill unmet needs of their patients through data, feedback and research.

Learning Objectives:

- Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
- Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population
- Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial

Slide Deck Link: <https://app.box.com/s/c2ghod5132iklbl76akbtqg2b126ui1h>